Provided by Tiger Trade Technology Pte. Ltd.

WUXI XDC

71.250
+1.3001.86%
Volume:8.63M
Turnover:611.95M
Market Cap:90.35B
PE:63.62
High:72.050
Open:70.700
Low:69.200
Close:69.950
52wk High:85.500
52wk Low:43.500
Shares:1.27B
HK Float Shares:1.27B
Volume Ratio:0.31
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.120
ROE:16.33%
ROA:9.32%
PB:6.86
PE(LYR):63.62
PS:11.16

Loading ...

Morgan Stanley Assigns "Overweight" Rating to WUXI XDC (02268) with HK$86 Price Target

Stock News
·
Mar 24

From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector

Stock News
·
Mar 24

Pharmaceutical Sector Leads Hong Kong Market Rebound with Strong ETF Performance

Deep News
·
Mar 24

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

Stock Track | WUXI XDC Soars 5.22% Intraday on Strong Fiscal Year Results

Stock Track
·
Mar 24

BRIEF-Wuxi Xdc Cayman Inc Posts FY Adjusted Net Profit Attributable RMB1.56 Billion

Reuters
·
Mar 23

WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate Crdmo

THOMSON REUTERS
·
Mar 23

WUXI XDC (02268) Maintains Strong 2025 Performance, Strengthens Leadership Through Global Expansion and Technology

Stock News
·
Mar 23

WuXi XDC posts 46.7% revenue jump to RMB 5.94 bn in 2025, sets RMB 8 bn capex plan to deepen global bioconjugate CDMO leadership

Bulletin Express
·
Mar 23

WUXI XDC Reports Double-Digit Growth in 2025 Revenue and Net Profit

Stock News
·
Mar 23

Wuxi XDC FY2025 gross profit jumps 72.5% to RMB 2.14 billion

Reuters
·
Mar 23

WuXi XDC Cayman FY Revenue RMB 5,944.2 Million

THOMSON REUTERS
·
Mar 23

BIODLINK-B Surges Over 11% Again, Shares Double This Year as WUXI XDC Takeover Becomes Effective

Stock News
·
Mar 20

BIODLINK-B Surges Over 9% as WUXI XDC's Takeover Offer Becomes Effective

Stock News
·
Mar 19

WuXi XDC Cayman says BioDlink tender offer turns unconditional after 60% share acceptances

Reuters
·
Mar 17

BIODLINK-B Shares Surge Over 5% in Afternoon Trading as WUXI XDC Acquisition Deadline Extended

Stock News
·
Mar 17

CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others

Stock News
·
Mar 17

HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Tiger Newspress
·
Mar 17

WuXi XDC extends BioDlink cash offer deadline to March 27 after 47% share acceptances

Reuters
·
Mar 13